Diabetes in 21% of real-world pulmonary fibrosis cohorts, well above the trial populations

Design

systematic review and meta-analysis of 251 observational studies, searched to August 2024

Population

606,398 adults with idiopathic pulmonary fibrosis in clinical cohorts

Primary outcome

pooled prevalence of comorbidities, with outcome associations synthesised narratively

Effect

diabetes 21% (95% CI 19-23); overweight or obesity 22% (18-27); dyslipidaemia 30% (20-38); hypertension 39% (34-44)

A systematic review pooled 251 observational studies of at least 100 adults each with idiopathic pulmonary fibrosis, 606,398 patients in total, and estimated the prevalence of every comorbidity reported. Diabetes was present in 21% (95% CI 19 to 23). Around it sat hypertension at 39% (34 to 44), dyslipidaemia at 30% (20 to 38), overweight or obesity at 22% (18 to 27), ischaemic heart disease at 20% and heart failure at 15%.

The comparison the authors draw is with IPF trial cohorts, where these rates are lower. That is the usual direction of trial selection, but it has a specific consequence here: the patient an endocrinologist is asked to see is more metabolically complicated than the evidence base for their lung disease assumed. Corticosteroid exposure during exacerbations, antifibrotic-related weight loss and appetite change, and reflux treated with long-term acid suppression all sit on top of that.

What the review could not do is tell you whether any of this alters the lung disease. Associations with quality of life and with progression were rarely studied and were synthesised narratively rather than pooled. Lung cancer was the only comorbidity consistently linked to mortality. So the practical reading is about co-management, not about screening for a new indication: if you are asked to take on glycaemia in someone with IPF, expect steroid-driven swings and unintentional weight loss to be the two things confusing the picture.

• Ask what antifibrotic the patient is on and whether weight loss has been attributed to it
• Anticipate steroid-induced hyperglycaemia around exacerbations and agree a plan in advance rather than during one
• Do not read unintentional weight loss in IPF as improving diabetes control
• Check lipids and blood pressure - both are commoner in these cohorts than diabetes is
• Record who is leading the glycaemic plan; co-managed patients are where sick-day advice goes missing

Why it matters

The IPF patient referred for glycaemic help is more metabolically loaded than the trial evidence behind their lung treatment assumed.

Don't overread it

This is a prevalence synthesis of observational cohorts - it does not show that diabetes worsens pulmonary fibrosis, or that treating it changes the lung disease.

The statistics, in plain English

The diabetes estimate is tight - 19 to 23% across 251 studies - so the prevalence itself is well established. Others are not: hiatus hernia ran from 9 to 33%, dyslipidaemia from 20 to 38%, which means the studies disagreed enough that the single pooled number is not worth quoting to a patient. Note also that prevalence tells you how often two conditions appear together and nothing about why; nothing here separates shared risk factors, treatment effects and chance.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.